60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.

Details

Ressource 1Download: 32210908_BIB_12570E9CE817.pdf (430.11 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_12570E9CE817
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
Journal
Frontiers in neurology
Author(s)
Kaufmann M., Puhan M.A., Salmen A., Kamm C.P., Manjaly Z.M., Calabrese P., Schippling S., Müller S., Kuhle J., Pot C., Gobbi C., Steinemann N., von Wyl V.
Working group(s)
Swiss Multiple Sclerosis Registry (SMSR)
ISSN
1664-2295 (Print)
ISSN-L
1664-2295
Publication state
Published
Issued date
2020
Peer-reviewed
Oui
Volume
11
Pages
156
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Background: Multiple sclerosis (MS) is the most common chronic, non-traumatic, neurologic disease in young adults. While approximate values of the disease burden of MS are known, individual drivers are unknown. Objective: To estimate the age-, sex-, and disease severity-specific contributions to the disease burden of MS. Methods: We estimated the disease burden of MS using disability-adjusted life years (DALYs) following the Global Burden of Disease study (GBD) methodology. The data sources consisted of the Swiss MS Registry, a recent prevalence estimation, and the Swiss mortality registry. Results: The disease burden of MS in Switzerland in 2016 was 6,938 DALYs (95%-interval: 6,018-7,955), which corresponds to 97 DALYs per 100,000 adult inhabitants. Morbidity contributed 59% of the disease burden. While persons in an asymptomatic (EDSS-proxy 0) and mild (EDSS-proxy >0-3.5) disease stage represent 68.4% of the population, they make up 39.8% of the MS-specific morbidity. The remaining 60.2% of the MS-specific morbidity stems from the 31.6% of persons in a moderate (EDSS-proxy 4-6.5) or severe (EDSS-proxy ≥7) disease stage. Conclusions: Morbidity has a larger influence on the disease burden of MS than mortality and is shared in a ratio of 2:3 between persons in an asymptomatic/mild and moderate/severe disease stage in Switzerland. Interventions to reduce severity worsening in combination with tailored, symptomatic treatments are important future paths to lower the disease burden of MS.
Keywords
DALY, SMSR, burden, epidemiology, morbidity, mortality
Pubmed
Open Access
Yes
Create date
01/04/2020 18:25
Last modification date
15/01/2021 7:08
Usage data